Insider · CIK 0002032049
Lucy To
Files at SABS (SAB Biotherapeutics, Inc.). First filing -, latest -.
In brief
Lucy To files SEC Form 4 as officer at SABS (SAB Biotherapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Lucy To has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 2 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 3, 2026 | SABS SAB Biotherapeutics, Inc. | AGrant or award Stock option (right to buy)derivative | +2,400,000 | $0.00 | $0 | 2,400,000 | Feb 5, 2026 |
| Aug 26, 2025 | SABS SAB Biotherapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +1,200,000 | $0.00 | $0 | 1,200,000 | Aug 28, 2025 |
Questions about Lucy To
Answered from the filings on this page, as of the latest one.
Is Lucy To buying or selling?
Lucy To has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Lucy To's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Lucy To has 0.
Where does Lucy To file Form 4?
Lucy To has filed Form 4 at SABS (SAB Biotherapeutics, Inc.) as See Remarks. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.